Table 1.

Baseline characteristics of recipients

Recipient Characteristics (total N=782)Alemtuzumab (N=87)Basiliximab (N=522)ATG (N=173)P Value
Sex, n (%)0.45
 Male59 (68)356 (68)109 (63)
 Female28 (32)166 (32)64 (37)
Race, n (%)0.01
 White71 (82)395 (76)123 (71)
 Black7 (8)65 (12)34 (20)
 Other9 (10)62 (12)16 (9)
Age at transplant (yr), mean (range)47.9 (18.6–69.6)54.9 (20.8–81.4)51.2 (18.8–73.0)<0.001
BMI (kg/m2), mean (range)29.2 (19.2–40.4)28.6 (16.3–47.6)28.3 (16.3–40.8)0.44
Blood transfusion, n (%)25 (29)229 (44)86 (50)<0.02
Previous kidney transplant, n (%)8 (9)42 (8)38 (22)<0.001
Pretransplant dialysis, mo21.626.626.00.75
End cPRA, % mean±SD7.7±22.612.6±27.024.7±37.6<0.001
HLA mismatch, mean±SD (out of 6)4.0±1.53.9±1.53.8±1.70.69
Belatacept, n (%)21 (24)1 (0.2)17 (10)<0.001
Early steroid withdrawal, n (%)76 (87)5 (1)39 (23)<0.001
  • ATG, anti-thymocyte globulin; BMI, body mass index; cPRA, calculated panel-reactive antibody.